Bionano Genomics, Inc. (BNGO)

Market Cap	9.92M
Revenue (ttm)	28.46M
Net Income (ttm)	-83.70M
Shares Out	3.36M
EPS (ttm)	-48.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,532
Open	3.000
Previous Close	3.010
Day's Range	2.920 - 3.010
52-Week Range	2.680 - 39.594
Beta	2.06
Analysts	Buy
Price Target	7.33 (+148.48%)
Earnings Date	Aug 11, 2025

About ANSS

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome anal...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 21, 2018
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: BNGO
• Website: https://bionano.com

Financial Performance

In 2024, Bionano Genomics's revenue was $30.78 million, a decrease of -14.79% compared to the previous year's $36.12 million. Losses were -$112.02 million, -51.82% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price target is $7.33, which is an increase of 148.48% from the latest price.

Price Target

$7.33

(148.48% upside)

Analyst Consensus: Buy